Finepoint Capital LP reported 3 positions worth $460.76M for the quarter ended Jun 30, 2026, up 10.7% on the prior quarter. It opened 0 new positions, added to 1, trimmed 1 and exited 0. Its largest holding is QXO, Inc. at 67.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| QXO QXO, Inc. | +4.26M | +30.7% | $73.53M | 67.93% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| RXO RXO, Inc. | -4.72M | -46.8% | $130.17M | 32.07% |
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | QXO QXO, Inc. | Industrials | 18.11M | $313.01M | 67.93% | +4.26M | +30.7% | Added | 2.36% |
| 2 | RXO RXO, Inc. | Industrials | 5.36M | $147.76M | 32.07% | -4.72M | -46.8% | Reduced | 3.16% |
| 3 | CLDI Calidi Biotherapeutics, Inc. | Healthcare | 65 | $177.00 | <0.01% | 0 | 0.0% | Unchanged | 0% |
Tip. Select a row to see that position’s full history at Finepoint Capital.
As of its Q2 2026 13F filing, Finepoint Capital LP’s five largest positions were QXO, Inc. (QXO) at 67.9%, RXO, Inc. (RXO) at 32.1%, Calidi Biotherapeutics, Inc. (CLDI) at 0.0% of the reported portfolio.
Finepoint Capital LP reported a 13F portfolio worth $460.76M across 3 positions for Q2 2026. That is up 10.7% from the previous quarter.
Its largest purchases by value were QXO, Inc. ($73.53M). It opened 0 new positions.
Its largest sales by value were RXO, Inc. ($130.17M). It exited 0 positions entirely.
From the Form 13F-HR reports Finepoint Capital LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.